PR Newswire: news distribution, targeting and monitoring
2014

Impact of Patent Expiration on Key Drugs Categories for 2012-2016 - A Survey Report

Share with Twitter Share with LinkedIn

NEW YORK, Dec. 31, 2012 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Impact of Patent Expiration on Key Drugs Categories for 2012-2016 - A Survey Report

http://www.reportlinker.com/p01055031/Impact-of-Patent-Expiration-on-Key-Drugs-Categories-for-2012-2016----A-Survey-Report.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_and_Medication

TechNavio's analysts have conducted a survey on Impact of Patent Expiration on Key Drugs Categories for 2012-2016. The survey assessed the Impact of Patent Expiration on several key drugs categories such as Antipsychotic drugs, Antibiotics, ADHD drugs, Antacid drugs, Antiplatelet drugs, Asthma drugs, Diabetes drugs, Arthritis drugs, HIV drugs, Epilepsy drugs, and Cardiovascular drugs. The survey also covers the strategies adopted before patent expiration, strategies adopted to counter patent expirations, organizational impacts, and their sales impacts. Based on the overall factors, the impact of patent expiration on key drugs categories was studied for the period 2012-2016.

TechNavio's report, Impact of Patent Expiration on Key Drugs Categories for 2012-2016 - A Survey Report, has been prepared based on responses from over 200 participants across patented drug manufacturers, generic drug manufacturers, and a combination of both. The survey participants were selected from more than 15 top countries in the Global Pharmaceuticals market.

The vendors mentioned in the report are ABX GmbH, Ache Laboratorios SA, ACI Limited, Ajanta Pharma Ltd., Alphapharm Pty Ltd., AstraZeneca Europe, AstraZeneca India, Astrazeneca do Brasil LTDA, Baxter Pharmaceuticals, Bayer Healthcare, Boehringer Ingelheim, CCL Pharmaceuticals Pvt. Ltd., Cipla Ltd., Covidien India Healthcare Limited, Dr Reddy's Laboratories Ltd., Eurofarma Laboratories Ltd., Ferring Pharmaceuticals, Genus Pharmaceuticals Ltd., Glenmark Pharmaceuticals, Healthcare Pharmaceuticals Ltd., Hospira Australia Pty Ltd., iNova Pharmaceuticals, LEO Pharma, Medley Pharmaceuticals Ltd., Merck Sharp & Dohme, MSD Pharmaceuticals Pvt. Ltd., Novartis International AG, Novartis de Colombia, Novartis farma Italy, Panacea Biotec Ltd., Pfizer Inc., PharmOut Pty Ltd., APP Pharmaceuticals, F. Hoffmann-La Roche Ltd., Sandoz GmbH, Sandoz India Pvt Ltd., Sanofi SA, Schwabe Pharmaceuticals, Torrent Pharma, Vifor Pharma Ltd., Wanbury Ltd, and Wockhardt Ltd.

Key questions answered in this report:

What will the market size be in 2016 and what will the growth rate be?

What are the key market trends?

What is driving this market?

What are the challenges to market growth?

Who are the key vendors in this market space?

What are the market opportunities and threats faced by the key vendors?

What are the strengths and weaknesses of the key vendors?

You can request one free hour of analyst time when you purchase this report. Details provided within the report.

TechNavio's research portfolio in the Healthcare series includes reports on the Pharmaceutical Market, Medical Devices Market, Diagnostic Market, Vaccine Market, Oncology Market, CRO Market, Orthopedic Market, Hearing Aids Market, Dental Care Market, Medical Imaging Market, Endoscopy Market, Dialysis Market, Telemedicine Market, Cancer Drug Market, Glucose Monitoring Market, Infusion Pumps Market, Defibrillators Market, Neuromodulation Market, Capnography Market.

Methodology

Research methodology is based on extensive primary and secondary research. Primary research includes in-depth interviews with industry experts, vendors, resellers and customers. Secondary research includes Technavio Platform, industry publications, company reports, news articles, analyst reports, trade associations and the data published by Government agencies.

01. Introduction

02. Scope of the Study

Overview

Objective

Survey Respondents

Selection Methodology

Selection Criteria

03. Respondent Profile

Profile by Designations

Profile by Nature of Work

Profile by Country

04. Industry Background

Business Type of the Companies

Number of Years in the Pharmaceutical Business

Medicinal Segments of Organizations

List of Companies that Participated in the Survey

05. Strategies Adopted Before Patent Expirations

Timeframe for Action Plan

Taking Part in a Merger or Acquisition

Phasing Out the Product

Rebranding the Product

Increasing the Market Penetration

Developing New and Alternative Products

Entering the Biosimilars Market

Reducing the Sales Force

Consolidated List of Responses for Strategies Adopted by Pharmaceutical Companies

Consolidated List of Responses for Strategies Adopted by Patented Drug Manufacturers Companies

06. Impact of Patent Expirations on Sales of Drugs in Key Drugs Categories

Antipsychotic Drugs

Antibiotics

ADHD Drugs

Antacid Drugs

Antiplatelet Drugs

Asthma Drugs

Diabetes Drugs

Arthritis Drugs

HIV Drugs

Epilepsy Drugs

Cardiovascular Drugs

Impact of Patent Expirations on the Sales of Drugs in Key Drug Categories

07. Strategies Adopted by Organizations to Counter the Impact of Patent Expiration

Launching New Products

Altering the Product

Phasing Out the Product

Reducing the Price of the Product

Increasing Marketing Activities

Rebranding the Product

Forming Strategic Alliances

Increasing Market Penetration

Entering New Markets

Consolidation of Strategies Adopted by Organizations to Counter the Impact of Patent Expiration

08. Organizational Impacts of Patent Expiration

Impact on Product Pricing

Impact on Marketing Expenses

Impact on Product Sales

Impact on R&D Investments

Impact on New Product Launches

Impact on Brand Equity

Consolidation of Major Organizational Impacts of Patent Expiration

09. Impact of Patent Expirations on Sales of OTC and Prescription Drugs

Sales of OTC Drugs

Sales of Prescription Drugs

10. Scenario of Pharmaceuticals after Patent Expirations

Entry of New Suppliers

Changes in Ingredients and Composition of Drugs

Change in Brand Name

11. Conclusion

12. Other Reports in this Series

List of Exhibits:

Exhibit 1: Survey Respondents

Exhibit 2: Methodology for Conducting the Survey

Exhibit 3: Respondent Profile by Designations

Exhibit 4: Respondent Profile by Nature of Work

Exhibit 5: Respondents by Country

Exhibit 6: Business Type of the Pharmaceutical Companies

Exhibit 7: Number of Years in Pharmaceutical Business

Exhibit 8: Medicinal Segments of Organizations

Exhibit 9: Timeframe for Action Plan to Counter Drug Patent Expiration

Exhibit 10: Taking Part in a Merger or Acquisition

Exhibit 11: Phasing Out the Product

Exhibit 12: Rebranding the Product

Exhibit 13: Increasing the Market Penetration

Exhibit 14: Developing New and Alternate Products

Exhibit 15: Entering the Biosimilars Market

Exhibit 16: Reducing the Sales Force

Exhibit 17: Responses for Strategies Adopted by Pharmaceutical Companies

Exhibit 18: Responses for Strategies Adopted by Patented Drug Manufacturers

Exhibit 19: Impact of Patent Expirations on Sales of Antipsychotic Drugs

Exhibit 20: Impact of Patent Expirations on Sales of Antibiotic Drugs

Exhibit 21: Impact of Patent Expirations on Sales of ADHD Drugs

Exhibit 22: Impact of Patent Expirations on Sales of Antacid Drugs

Exhibit 23: Impact of Patent Expirations on Sales of Antiplatelet Drugs

Exhibit 24: Impact of Patent Expirations on Sales of Asthma Drugs

Exhibit 25: Impact of Patent Expirations on Sales of Diabetes Drugs

Exhibit 26: Impact of Patent Expirations on Sales of Arthritis Drugs

Exhibit 27: Impact of Patent Expirations on Sales of HIV Drugs

Exhibit 28: Impact of Patent Expirations on Sales of Epilepsy Drugs

Exhibit 29: Impact of Patent Expirations on Sales of Cardiovascular Drugs

Exhibit 30: Impact of Patent Expirations on the Sales of Drugs in Key Drug Categories

Exhibit 31: Launching New Products

Exhibit 32: Altering the Product

Exhibit 33: Phasing Out the Product

Exhibit 34: Reducing the Price of the Product

Exhibit 35: Increasing Marketing Activities

Exhibit 36: Rebranding the Product

Exhibit 37: Forming Strategic Alliances

Exhibit 38: Increasing Market Penetration

Exhibit 39: Entering New Markets

Exhibit 40: Consolidation of Strategies Adopted by Organizations to Counter the Impact of Patent Expiration

Exhibit 41: Impact on Product Pricing

Exhibit 42: Impact on Marketing Expenses

Exhibit 43: Impact on Product Sales

Exhibit 44: Impact on R&D Investments

Exhibit 45: Impact on New Product Launches

Exhibit 46: Impact on Brand Equity

Exhibit 47: Consolidation of Major Organizational Impacts of Patent Expiration

Exhibit 48: Sales of Over-the-Counter Drugs

Exhibit 49: Sales of Prescription Drugs

Exhibit 50: Entry of New Suppliers

Exhibit 51: Changes in Ingredients and Composition of Drugs

Exhibit 52: Change in Brand Name

To order this report:

Drug_and_Medication Industry: Impact of Patent Expiration on Key Drugs Categories for 2012-2016 - A Survey Report

Contact Nicolas: nicolasbombourg@reportlinker.com
US: (805)-652-2626
Intl: +1 805-652-2626

SOURCE Reportlinker



RELATED LINKS
http://www.reportlinker.com

Featured Video

Journalists and Bloggers

Visit PR Newswire for Journalists for releases, photos, ProfNet experts, and customized feeds just for Media.

View and download archived video content distributed by MultiVu on The Digital Center.

Share with Twitter Share with LinkedIn
 

Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

 

 
 

PR Newswire Membership

Fill out a PR Newswire membership form or contact us at (888) 776-0942.

 
 

Learn about PR Newswire services

Request more information about PR Newswire products and services or call us at (888) 776-0942.

 

Online Member Center

Not a Member?
Click Here to Join
Login
Search News Releases
Advanced Search
Search
  1. PR Newswire Services
  2. Knowledge Center
  3. Browse News Releases
  4. Contact PR Newswire
  5. Send a News Release